X0206 3 2021-09-27 0 0000827871 EAGLE PHARMACEUTICALS, INC. EGRX 0001886788 Moran Michael Shawn C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE NJ 07677 0 1 0 0 EVP, Chief Commercial Officer Common Stock 24268 D Employee Stock Option (right to buy) 66.32 2026-01-27 Common Stock 10000 D Employee Stock Option (right to buy) 84.92 2027-01-03 Common Stock 27000 D Employee Stock Option (right to buy) 59.14 2028-01-06 Common Stock 5000 D Employee Stock Option (right to buy) 41.37 2029-01-29 Common Stock 1594 D Employee Stock Option (right to buy) 59.79 2030-01-05 Common Stock 37500 D 20,828 of the shares represent restricted stock units ("RSU") awards. The RSUs shall vest: 253 RSUs on January 7, 2022; 563 RSUs on January 29, 2022; 562 RSUs on January 29, 2023; 3,750 RSUs on each of January 5, 2022, January 5, 2023 and January 5, 2024; and 2,050 RSUs on each of February 2, 2022, February 2, 2023, February 2, 2024 and February 2, 2025, subject to the Reporting Person's continuous service through each vesting date. The options are fully vested and exercisable. One fourth (1/4th) of the shares underlying the option vested on January 7, 2019, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date. The option grant was initially 4,500 shares of which one fourth (1/4th) of the shares underlying the option vested on January 29, 2020, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date. One fourth (1/4th) of the shares underlying the option vested on January 5, 2021, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date. /s/ Brian Cahill, Attorney-in-Fact 2021-10-07